Clinical study on pegaspargase combined with EPOCH regimen in the treatment of relapse and refractory non-Hodgkin's T-cell lymphoma

Abstract

Objective To observe the effect and toxicity of pegaspargase combined with EPOCH(P-EPOCH)regimen for patients with relapse and refractory non-Hodgkin's' T-cell lymphoma(T-NHL). Methods A total of 15 patients with pathologically diagnosed T-NHL from January 2010 to January 2014 of the Beijing Military Region General Hospital who had been treated with CHOP or CHOP-like regimens were relapse or refractory. They were treated by P-EPOCH regimen [VP16 50 mg/m2, E-ADM 12 mg/m2, VCR 0.4 mg/m2, dissolved in 500 ml saline sustained static drops 24 h on day 1 to 4; CTX 750 mg/m2, intravenous injection on day 5; pegaspargase 2 500 U·m-2·d-1 given as intramuscular injection on day 6; oral prednisone 60 mg/m2 on day l to 6; 21 days of a cycle]. Results All the 15 patients were treated by P-EPOCH regimen. The response rate of the whole group was 66.7 %, including CR 4 cases(26.7 %)and PR 6 cases(40.0 %). The median survival time was 20 months(5-30 months), and(2-year)overall survival rate was 46.6 %. Main side effects were myelosuppression, liver dysfunction and disturbance of blood coagulation. Conclusion P-EPOCH regimen is effective for patients with relapse and refractory T-NHL and has better tolerance, and wovthy of clinical study. Key words: Pegaspargase; EPOCH regimen; Non-Hodgkin's T-cell lymphoma; Treatment outcome